focus -WSS

focus

author：explore 2025-10-01 02:27:32 - browse：1

A person picking up medication at a drive through pharmacy window – biotech and pharma coverage from STAT — Adobe

On Tuesday morning, the Department of Health and Human Services unveiled its long-awaited list of the 10 medicines that will be subject to price negotiation in 2026 under the Inflation Reduction Act.

This will mark the first time that Medicare, the government program for paying for health care for older Americans, will have any ability to use its vast size to negotiate for lower prices. It’s not yet clear how big the discounts on these 10 drugs will be, or even if the law will hold up to multiple legal challenges from the pharmaceutical industry. It’s also not clear, as critics from the drug industry have noted, whether any savings to the government will be passed on to consumers.

Still, the naming of 10 medicines is a milestone, and a point to start appraising the impact of the law. The landscape here is complicated. No one really knows how the IRA’s price negotiation process will play out over the short and long term, and many companies who had products named were spared in other ways, with products many industry watchers expected to see on the list absent. Here is STAT’s assessment of who has won and lost.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： FDA approval of Sarepta Duchenne genetic therapy gives me hope
Next article： Novo Nordisk to expand supply of Wegovy for U.S. patients

explore

WSS

Israeli protesters block highways, train stations as Netanyahu moves ahead with judicial overhaul

Robert Kennedy Jr.'s presidential campaign attracts GOP

Asa Hutchinson previews new plan to reform federal law enforcement if elected in 2024

Robert Kennedy Jr.'s presidential campaign attracts GOP

Twill hunts for pharma partner to market its depression app

Phoenix breaks record with 19 consecutive days above 110 degrees Fahrenheit

hotspot

focus

focus

Biden outlines 'new path' to provide student loan relief after Supreme Court rejection

House passes resolution saying Israel isn't a 'racist or apartheid state'

In age of alternative facts, a scholarly course on calling out crap

Phoenix breaks record with 19 consecutive days above 110 degrees Fahrenheit

At least 13 dead in Texas as scorching temps continue

Congressmen charge Covid hearing ‘could have been an email’

Medicare proposal to cover medical devices draws a mixed reaction

FDA drug safety: Singulair case shows systemic surveillance flaws

At least 13 dead in Texas as scorching temps continue

Cognito secures funding to test medical device for Alzheimer's

entertainment

A strong 6.5

ER docs worry over extreme heat as a 'mass casualty event'

Robert Kennedy Jr.'s presidential campaign attracts GOP

In a test for AI, buzzy startup Insitro inks drug discovery deal with Gilead

Apple Vision Pro: A first look at health apps on the new VR headset

Readout LOUD podcast: Vertex data, Aduhelm, & Woodcock retires

knowledge

explore

explore

knowledge